Singapore markets close in 3 hours 57 minutes

Eupraxia Pharmaceuticals Inc. (EPRX.TO)

Toronto - Toronto Real-time price. Currency in CAD
Add to watchlist
2.00000.0000 (0.00%)
At close: 03:06PM EST
Full screen
Loading interactive chart…
  • CNW Group

    Eupraxia Pharmaceuticals Inc. Provides Update on its Phase 2 Trial for Osteoarthritis Drug Candidate EP-104IAR

    December 2, 2021 - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clinical-stage biotechnology company with an innovative drug delivery platform technology, today provided an update on its ongoing Phase 2 trial that is evaluating the safety and efficacy of its drug candidate EP-104IAR as a treatment for knee osteoarthritis.

  • CNW Group

    Eupraxia Pharmaceuticals Inc. Reports Third Quarter 2021 Financial Results

    Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced its unaudited financial results (prepared in accordance with International Financial Reporting Standards or "IFRS") and operational highlights for the third quarter ended September 30, 2021. All amounts are expressed in Canadian dollars unless otherwise noted.

  • CNW Group

    Eupraxia Pharmaceuticals Inc. Announces Research and Development Funding

    Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery platform technology, today announced it is receiving advisory services and funding up to $700,000 from the National Research Council of Canada Industrial Research Assistance Program ("NRC IRAP") to support a research and development project to further develop the Company's polymer-based proprietary drug delivery technology.